We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
BTG | LSE:BGC | London | Ordinary Share | GB0001001592 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 387.50 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
04/4/2012 17:04 | txi..echo your views in post 20111 above, in respect of CEO's comments re CytoFab. This extra £29m turnover will both fall straight to the bottom line and into bank balances. Can't see company paying divi this time round, probably will keep cash to fund acquisitions. Dividends will start when Varisolve hopefully approved and marketed. Exciting times ahead with so much more to come! | toffeeman4 | |
04/4/2012 14:00 | Have the yanks heard the news-some signs of life back this afternoon. Against a spooked market as well. | fhmktg | |
04/4/2012 13:54 | More , excellent | doctor 69 | |
04/4/2012 10:25 | 04-04-12 Jefferies International Buy Recommendation and Target Price Raised from 345 to 410 | moretimeforlife | |
04/4/2012 09:37 | Excellent pre results summary I would like to think that Louise would not have said that there was a busy period ahead including "data from Astrazeneca's Phase IIb study of AZD9773." unless she/BTG believed that there might be a positive outcome? | txi | |
04/4/2012 08:03 | Alan you are correct , but I think zytiga sales will have rocketed and continue to do so , | doctor 69 | |
04/4/2012 07:28 | Good progress. However don't forget that the better than anticipated revenues from BeneFix are in effect a one-off. As the RNS does not split the additional £30m between BeneFix and Zyiga we have no way of knowing how much of the £30m will hopefully continue into the future. Nonetheless very pleasing. | alanrussell | |
04/4/2012 07:06 | If revenues are going to be 20% ahead profits must be well ahead surely? 195m revs aren't forecast for another 2 years CR | cockneyrebel | |
04/4/2012 06:59 | Agree, doc, will imo supercede stripping. Surgeons still do loads of those because many are hesitant due to potential medico-legal implications of using (even a tried and tested but unregulated) otc product for this procedure. Give them a regulated product and this will change. BTG will need to get the pricing right-clearly more expensive with margin but not so much so that it deters doctors in this cost concious world. Margins can be lower though because the market is massive. imo | cumnor | |
04/4/2012 06:50 | cumnor mature comments, but agree especially the world does not realise how big varizolve is. i have seen this with vascular surgeons in our theatre moving out to use foam ( off shelf). What this means to me is when on market in usa , this will explode in sales and BTG get most of the money for this. | doctor 69 | |
04/4/2012 06:47 | Serious stuff. This company s heading in the right direction and for many of it's present products sales imo are just only beginning to tick up. Some are indispensible, niche with very decent margins and the beads will soon start to deliver. Cytofab the markethas discounted as unlikely to succeed but this is already in the share price given the stats. If it did then £20 per share to begin with. Varisolve (people don't realise how huge the market is for a 'regulated' product')hopefully gets final push but I am very pleased with present products (they have taken on really good ones) which alone justifies mrkt cap). Safety first. What I like is it's very broad revenue generating portfolio and more to come. Not sure if we should just be one seventieth of mrkt cap of the likes of GSK with this model and pipeline. imo. | cumnor | |
04/4/2012 06:46 | Doc, trancending 400 before Results update on 21st May would be a very welcome confirmation that it is on track.....good luck. | moretimeforlife | |
04/4/2012 06:40 | more it has been a long time comming , but btg has some many irons in fire that even without sepsis treatment btg will get in to ftse 100 in next few years. They really should double from here over next 12 months. | doctor 69 | |
04/4/2012 06:36 | Doc/Ade, We have waiting many years for BTG to fulfil its promise and it feels good to see it on track to achieve significant value by 2013. Ade, well done on timing re. catching top and hope you get back in. Just as Au. eventually paid off even better than the 2010 by 2010 we wanted with 2550 in 2011, I am still expecting that BTG will achieve £7-£11 in next 21 months. With V and Cytofab making good progress on top of the very solid foundations of the existing revenue streams I am feeling very confident that BTG too will deliver significant value and could also exceed our expectations. Good luck to all fellow investors. NAI/DYOR etc | moretimeforlife | |
04/4/2012 06:29 | These should motor today. Patience being rewarded.And Varisolve still to come. | broadwood | |
04/4/2012 06:25 | mt still around and sold - pure luck - at the top to finance house purchase now have free funds and will be back in today this is no longer a blockbuster in the making looks well cooked to me and only going in one direction - i wonder who'll start the bidding? | adejuk | |
04/4/2012 06:17 | moretime stunning , espceially as they had alreadt raced target for year , but this is a big big jump ie nearly 20% jump in sales . With soo much to come out remaining part of year , this is very exciting. What a team btg have at the helm. interesting to see what broker upgrades come along. Typically with the ahre share we get a little rise and then we pause and go higher. we shoudl be pushing toward 400p on this over next month | doctor 69 | |
04/4/2012 06:11 | Wow....it keeps getting better and better :) "Trading within both the Specialty Pharmaceuticals and Interventional Medicine business areas has been in line with expectations. Trading in the Licensing & Biotechnology business area has been significantly ahead of expectations, driven by higher than anticipated royalties from BeneFIX® (factor IX) and Zytiga® (abiraterone acetate). As a result, BTG is raising its revenue estimate for the year ended 31 March 2012 from previous guidance of £160m-£165m to £190m-£195m." | moretimeforlife | |
03/4/2012 06:02 | More I am very confident that all that btg are doing will see a large share price as time progresses | doctor 69 | |
02/4/2012 19:31 | fh, expecting much more than £4.50 over next 21 months.....and won't complain if it happens sooner than that :) Good luck to all fellow investors. Ade, WB2, are you guys still around....and still invested? NAI/DYOR etc | moretimeforlife | |
02/4/2012 17:28 | Next leg up underway? £4.50 coming soon I hope! | fhmktg | |
02/4/2012 09:09 | Nice to see a couple of 10k 'O' buys on the first day of the new quarter- hopefully some ISA buys for the new year will kick in as well! Critical quarter for news coming up! | fhmktg | |
30/3/2012 16:39 | Well. ..the traders got their quarter-end sorted with a neutral end to the day. Lets hope for a continuation of optimism in the next - critical- quarter. Good luck fellow punters! | fhmktg | |
30/3/2012 14:54 | moretime....as long as all goes to plan don't disagree with either of those two scenarios. Management have done/are doing a good job, hope they have got it right with Varisolve. Assume CytoFab totally in the hands of AZ though. Importantly, institutional investors appear to have confidence in management to deliver. | toffeeman4 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions